EXPLORE!

ACE inhibitors, ARBs in COVID-19 may be tied to Acute Kidney Injury

  640 Views

#Cardiology  #Internal Medicine  #Nephrology  #Public Health 

eMediNexus    23 November 2021

The largest dataset of randomized controlled trials looking into the safety of ACE inhibitors and angiotensin receptor blockers in patients with COVID-19 demonstrated encouraging results; however, there was a new observation of an association with acute kidney injury in hospitalized patients.

The meta-analysis noted that there was about two times increased risk of acute kidney injury in hospitalized patients with the use of ACE inhibitors and angiotensin receptor blockers in acute COVID-19 (7% vs 3.6%). There was no effect of renin-angiotensin system blockers, in comparison with control, on all-cause mortality (7.2% vs 7.5%, relative risk 0.95), either overall or in subgroups characterized by severity or trial type (RASi initiation or continuation).

The new meta-analysis was presented at the American Heart Association (AHA) Scientific Sessions… (Medscape)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.